Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.cipla.com | |
Market Cap | 120,838.63 Cr. | |
Enterprise Value(EV) | 117,870.04 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 45.93 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 32.59 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.15 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 320.72 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.67 | Calculated using Price: 1,499.05 |
Dividend Yield | 0.57 | Period Ending 2023-03 |
No. of Shares Subscribed | 80.74 Cr. | 807,367,062 Shares |
FaceValue | 2 | |
About Cipla Ltd. | ||
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets. |
1 Day |
|
+1.94% |
1 Week |
|
+5.49% |
1 Month |
|
+0.41% |
3 Month |
|
+20.59% |
6 Month |
|
+26.61% |
1 Year |
|
+68.04% |
2 Year |
|
+47.50% |
5 Year |
|
+184.61% |
10 Year |
|
+287.42% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 12.1 | 12.61 | 8.72 | 10.65 | 10.37 | 10.09 | 14.13 | 13.1 | 12.85 | |
Return on Capital Employed (%) | 15.33 | 13.24 | 8.28 | 10.2 | 11.94 | 12.53 | 17.85 | 17.24 | 18.19 | |
Return on Assets (%) | 7.85 | 7.28 | 4.97 | 6.52 | 6.5 | 6.56 | 9.95 | 9.94 | 10.19 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 10,801 | 11,516 | 12,544 | 14,229 | 15,012 | 15,763 | 18,327 | 20,842 | 23,408 | 24,825 | |
Non Curr. Liab. | 2,418 | 1,407 | 4,513 | 4,259 | 4,646 | 2,972 | 1,660 | 622 | 184 | 146 | |
Curr. Liab. | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,033 | 5,648 | |
Minority Int. | 180 | 350 | 438 | 352 | 332 | 294 | 259 | 276 | 306 | 270 | |
Equity & Liab. | 17,281 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 29,007 | 30,889 | |
Non Curr. Assets | 9,689 | 12,208 | 12,064 | 11,859 | 11,335 | 11,717 | 11,628 | 11,925 | 11,732 | 11,882 | |
Curr. Assets | 7,591 | 8,841 | 8,736 | 10,814 | 12,425 | 11,704 | 13,181 | 14,711 | 16,805 | 19,007 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 17,281 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 29,007 | 30,889 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 11,345 | 13,595 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,350 | |
Other Income | 166 | 208 | 229 | 358 | 477 | 369 | 270 | 322 | 512 | 632 | |
Total Income | 11,511 | 13,803 | 14,623 | 15,513 | 16,839 | 17,501 | 19,429 | 22,085 | 23,265 | 25,982 | |
Total Expenditure | -9,184 | -11,115 | -11,919 | -12,329 | -13,265 | -13,951 | -14,911 | -17,251 | -17,763 | -19,201 | |
PBIDT | 2,327 | 2,688 | 2,704 | 3,184 | 3,574 | 3,550 | 4,518 | 4,834 | 5,502 | 6,781 | |
Interest | -168 | -207 | -159 | -114 | -168 | -197 | -161 | -106 | -110 | -107 | |
Depreciation | -505 | -754 | -1,323 | -1,323 | -1,326 | -1,175 | -1,068 | -1,052 | -1,172 | -1,109 | |
Taxation | -400 | -332 | -180 | -250 | -570 | -631 | -889 | -934 | -1,203 | -1,444 | |
Exceptional Items | -78 | -182 | -182 | -377 | |||||||
PAT | 1,254 | 1,395 | 1,042 | 1,419 | 1,510 | 1,547 | 2,401 | 2,559 | 2,835 | 3,744 | |
Minority Interest | -48 | -23 | -29 | -6 | 35 | 47 | 16 | -30 | -31 | -35 | |
Share Associate | -25 | -12 | -7 | -3 | -17 | -47 | -13 | -13 | -3 | -1 | |
Other Related Items | |||||||||||
Consolidated Net Profit | 1,181 | 1,360 | 1,006 | 1,411 | 1,528 | 1,547 | 2,405 | 2,517 | 2,802 | 3,708 | |
Adjusted EPS | 15 | 17 | 13 | 18 | 19 | 19 | 30 | 31 | 35 | 46 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 1,563 | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | |
Cash Fr. Inv. | -1,250 | -941 | -4,523 | -1,310 | -854 | -1,669 | 104 | -2,387 | -1,872 | -2,389 | |
Cash Fr. Finan. | -266 | 165 | 3,104 | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | -958 | |
Net Change | 48 | 397 | 322 | -254 | 223 | -326 | 224 | 129 | -146 | -109 | |
Cash & Cash Eqvt | 176 | 564 | 858 | 610 | 853 | 508 | 742 | 790 | 658 | 561 |
Tue, 26 Mar 2024
Announcement under Regulation 30 (LODR)-Restructuring Merger of Cipla Technologies LLC USA with Cipla USA Inc. USA wholly owned step down subsidiaries of the Company |
Tue, 26 Mar 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India |
Tue, 26 Mar 2024
Announcement under Regulation 30 (LODR)-Change in Management Pursuant to Regulation 30 of the SEBI Listing Regulations we hereby notify that Mr. Rajeev Kumar Sinha presently working as Global Head - Formulations Manufacturing has been appointed as Senior Management Personnel and Global Chief Manufacturing Officer w.e.f. 1st April 2024. |
Wed, 27 Mar 2024 |
High Delivery Percentage |
Close Within 52 Week High Zone |
High Increase in 3 Months |
High Increase in 6 Months |
High Increase in 1 Year |